Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 691 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... July 20, 2020 Black Patients Are More Likely to Die of Cancer—Here’s How One... December 21, 2021 Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local... August 27, 2024 Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... August 2, 2022 Load more HOT NEWS How I Learned to Cope With Survivor’s Guilt After Cancer Eflornithine Plus Sulindac Not Superior to Either Drug Alone in FAP Όροι χρήσης και προϋποθέσεις How I Navigated Being a Young Mom During Cancer: A Survivor’s...
